The 112 references in paper K. Мukhin Yu., O. Pylaeva A., К. Мухин Ю., О. Пылаева А. (2015) “Применение зонисамида (Зонеграна) в лечении эпилепсии у взрослых и детей (обзор зарубежной литературы и описание случая) // ZONISAMIDE (ZONEGRAN) IN THE TREATMENT OF EPILEPSY IN ADULTS AND CHILDREN (A REVIEW AND CLINICAL CASE)” / spz:neicon:rjdn:y:2015:i:1:p:47-63

1
Инструкция по применению лекарственного препарата для медицинского применения Зонегран®. http://medi.ru/doc/a4201. htm. [Instructions for application of the Zonegran® drug for human use. http://medi. ru/doc/a4201.htm. (In Russ.)].
(check this in PDF content)
2
Пылаева О.А., Мухин К.Ю. Применение зонисамида (зонегран) в лечении эпилепсии: акцент на монотерапию фокальных приступов (обзор зарубежной литературы). Русский журнал детской неврологии 2014;9(2):42–49. [Pylaeva O.A., Mukhin K.Yu. Application of zonisamide (zonegran) in the treatment of epilepsy: focus on monotherapy of focal seizures (foreign literature review). Russkiy zhurnal detskoi nevrologii = Russian Journal of Child Neurology 2014;9(2):42–9. (In Russ.)].
(check this in PDF content)
3
Пылаева О.А., Мухин К.Ю. Применение нового антиэпилептического препарата – зонегран (зонисамид) – в лечении эпилепсии (обзор литературы). Русский журнал детской неврологии 2012;7(2):13–34. [Pylaeva O.A., Mukhin K.Yu. Application of the new antiepileptic drugs – zonegran (zonisamide) – in the treatment of epilepsy (literature review). Russkiy zhurnal detskoi nevrologii = Russian Journal of Child Neurology 2012;7(2):13–34. (In Russ.)].
(check this in PDF content)
4
Afra P., Adamolekun B. Update on oncedaily zonisamide monotherapy in partial seizures. Neuropsychiatr Dis Treat 2014;10:493–8.
(check this in PDF content)
5
Arzimanoglou A., Rahbani A. Zonisamide for the treatment of epilepsy. Expert Rev Neurother 2006;6(9):283–92.
(check this in PDF content)
6
Baulac M. Introduction to zonisamide. Epilepsy Res 2006;68 Suppl 2:S3–9.
(check this in PDF content)
7
Baulac M., Brodie M.J., Patten A. et al. Efficacy and tolerability of zonisamide versus controlled-release carbamazepine for newly diagnosed partial epilepsy: a phase 3, randomised, double-blind, non-inferiority trial. Lancet Neurol 2012;11(7):579–88.
(check this in PDF content)
8
Baulac M., Leppik I.E. Efficacy and safety of adjunctive zonisamide therapy for refractory partial seizures. Epilepsy Res 2007;75(2–3):75–83.
(check this in PDF content)
9
Biton V. Clinical pharmacology and mechanism of action of zonisamide. Clin Neuropharmacol 2007;30(4):230–40.
(check this in PDF content)
10
Biton V. Zonisamide: newer antiepileptic agent with multiple mechanisms of action. Expert Rev Neurother 2004;4(6):935–43.
(check this in PDF content)
11
Bös M., Bauer J. Anticonvulsant treatment with zonisamide added to topiramate. A preliminary treatment analysis in 19 patients. Nervenarzt 2007;78(12):1425–9.
(check this in PDF content)
12
Brodie M.J. Zonisamide as adjunctive therapy for refractory partial seizures. Epilepsy Res 2006;68 Suppl 2:S11–6.
(check this in PDF content)
13
Brodie M.J. Zonisamide clinical trials: European experience. Seizure 2004;13 Suppl 1: S66–70; discussion S71–2.
(check this in PDF content)
14
Brodie M.J., Duncan R., Vespignani H. et al. Dose-dependent safety and efficacy of zonisamide: a randomized, double-blind, 6161 RGDN_01_2015 Block.indd 61RGDN_01_2015 Block.indd 6106.04.2015 13:44:4206.04.2015 13:44:42 placebo-controlled study in patients with refractory partial seizures. Epilepsia 2005;46(1):31–41.
(check this in PDF content)
15
Chadwick D.W., Marson A.G. Zonisamide add-on for drug-resistant partial epilepsy. Cochrane Database Syst Rev 2002;(2):CD001416.
(check this in PDF content)
16
Chadwick D.W., Marson A.G. Zonisamide add-on for drug-resistant partial epilepsy. Cochrane Database Syst Rev 2005;(4):CD001416.
(check this in PDF content)
17
Cohen A.F., van Bronswijk H. New medications; zonisamide. Ned Tijdschr Geneeskd 2006;150(42):2313.
(check this in PDF content)
18
Coppola G., Grosso S., Verrotti A. et al. Zonisamide in children and young adults with refractory epilepsy: an open label, multicenter Italian study. Epilepsy Res 2009;83(2–3):112–6.
(check this in PDF content)
19
Crawford P.M. Managing epilepsy in women of childbearing age. Drug Saf 2009;32(4):293–307.
(check this in PDF content)
20
DiMauro S., Hirano M. MERRF. In: Pagon R.A., Bird T.D., Dolan C.R., Stephens K. (ed.). GeneReviews [Internet]. Seattle (WA): University of Washington, 1993– 2003 Jun 03 [updated 2009 Aug 18].
(check this in PDF content)
21
Dupont S., Striano S., Trinka E. et al. Flexible dosing of adjunctive zonisamide in the treatment of adult partial-onset seizures: a non-comparative, open-label study (ZEUS). Acta Neurol Scand 2010;121(3):141–8.
(check this in PDF content)
22
Elger C.E., Schmidt D. Modern management of epilepsy: а practical approach. Epilepsy Behav 2008;12(4):501–39.
(check this in PDF content)
23
Faught E. Review of United States and European clinical trials of zonisamide in the treatment of refractory partial-onset seizures. Seizure 2004;13 Suppl 1:S59–65; discussion S71–2.
(check this in PDF content)
24
Fox M.H., Bassuk A.G. Progressive Myoclonus epilepsy with ataxia. In: Pagon R.A., Bird T.D., Dolan C.R., Stephens K. (ed.). GeneReviews [Internet]. Seattle (WA): University of Washington, 1993–2009 Sep 08.
(check this in PDF content)
25
Frampton J.E., Scott L.J. Zonisamide: a review of its use in the management of partial seizures in epilepsy. CNS Drugs 2005;19(4):347–67.
(check this in PDF content)
26
Fujii T., Furukama H., Matsumoto K. et al. Dainippon Pharmaceutical Co, Ltd, Developmental Laboratories. Data on file, 1989. Japanese.
(check this in PDF content)
27
Fujita Y., Hasegawa M., Nabeshima K. et al. Acute kidney injury caused by zonisamide-induced hypersensitivity syndrome. Intern Med 2010;49(5):409–13.
(check this in PDF content)
28
Fukuoka N., Tsukamoto T., Uno J. et al. Influence of coadministered antiepileptic drugs on serum zonisamide concentrations in epileptic patients: quantitative analysis based on suitable transforming factor. Biol Pharm Bull 2003;26(12):1734–8.
(check this in PDF content)
29
Fukushima K., Seino M. A long-term follow-up of zonisamide monotherapy. Epilepsia 2006;47(11):1860–4.
(check this in PDF content)
30
Gadde K.M., Franciscy D.M., Wagner H.R. 2nd, Krishnan K.R. Zonisamide for weight loss in obese adults: a randomized controlled trial. JAMА 2003;289(14):1820–5.
(check this in PDF content)
31
Glauser T., Ben-Menachem E., Bourgeois B. et al.; ILAE Subcommission on AED Guidelines. Updated ILAE evidence review of antiepileptic drug efficacy and effectiveness as initial monotherapy for epileptic seizures and syndromes. Epilepsia 2013;54(3):551–63.
(check this in PDF content)
32
Hayakawa T., Nejihashi Y., Kishi T. et al. Serum zonisamide concentration in fresh cases of childhood epilepsy following zonisamide monotherapy. J Jpn Epilepsy Soc 1994;12:249–54.
(check this in PDF content)
33
Hirai K., Kimiya S., Tabata K. et al. Selective mutism and obsessive compulsive disorders associated with zonisamide. Seizure 2002;11(7):468–70.
(check this in PDF content)
34
Hirose M., Yokoyama H., Haginoya K., Iinuma K. A five-year-old girl with epilepsy showing forced normalization due to zonisamide. No To Hattatsu 2003;35(3):259–63.
(check this in PDF content)
35
Hirose S., Kurahashi H. Autosomal dominant nocturnal frontal lobe epilepsy. In: Pagon R.A., Bird T.D., Dolan C.R., Stephens K. (ed.). GeneReviews [Internet]. Seattle (WA): University of Washington, 1993– 2002 May 16 [updated 2010 Apr 05].
(check this in PDF content)
36
Holder J.L. Jr., Wilfong A.A. Zonisamide in the treatment of epilepsy. Expert Opin Pharmacother 2011;12(16):2573–81.
(check this in PDF content)
37
Iinuma K., Haginoya K. Clinical efficacy of zonisamide in childhood epilepsy after longterm treatment: a postmarketing, multiinstitutional survey. Seizure 2004;13 Suppl 1: S34–9; discussion S40.
(check this in PDF content)
38
Italiano D., Pezzella M., Coppola A. et al. A pilot open-label trial of zonisamide in Unverricht-Lundborg disease. Mov Disord 2011;26(2):341–3.
(check this in PDF content)
39
Janszky J. Role of zonisamid in treating epilepsy, Parkinson disorders and other neurological diseases. Ideggyogy Sz 2009;62(11–12):383–9.
(check this in PDF content)
40
Joo E.Y., Kim H.J., Lim Y.H. et al. Zonisamide changes unilateral cortical excitability in focal epilepsy patients. J Clin Neurol 2010;6(4):189–95.
(check this in PDF content)
41
Joo E.Y., Kim S.H., Seo D.W., Hong S.B. Zonisamide decreases cortical excitability in patients with idiopathic generalized epilepsy. Clin Neurophysiol 2008;119(6): 1385–92.
(check this in PDF content)
42
Kelemen A., Rasonyl G., Neuwirth M. et al. Our clinical experience with zonisamide in resistant generalized epilepsy syndromes. Ideggyogy Sz 2011;64(5–6):187–92.
(check this in PDF content)
43
Kelley S.A., Kossoff E.H. Doose syndrome (myoclonic-astatic epilepsy): 40 years of progress. Dev Med Child Neurol 2010;52(11):988–93.
(check this in PDF content)
44
Kim H.L., Aldridge J., Rho J.M. Clinical experience with zonisamide monotherapy and adjunctive therapy in children with epilepsy at a tertiary care referral center. J Child Neurol 2005;20(3):212–9.
(check this in PDF content)
45
Kluger G., Zsoter A., Holthausen H. Longterm use of zonisamide in refractory childhood-onset epilepsy. Eur J Paediatr Neurol 2008;12(1):19–23.
(check this in PDF content)
46
Kothare S.V., Kaleyias J. Zonisamide: review of pharmacology, clinical efficacy, tolerability, and safety. Expert Opin Drug Metab Toxicol 2008;4(4):493–506.
(check this in PDF content)
47
Kothare S.V., Kaleyias J., Mostofi N. et al. Efficacy and safety of zonisamide monotherapy in a cohort of children with epilepsy. Pediatr Neurol 2006;34(5):351–4.
(check this in PDF content)
48
Kothare S.V., Valencia I., Khurana D.S. et al. Efficacy and tolerability of zonisamide in juvenile myoclonic epilepsy. Epileptic Disord 2004;6(4):267–70.
(check this in PDF content)
49
Kumagai N., Seki T., Yamawaki H. et al. Monotherapy for childhood epilepsies with zonisamide. Jpn J Psychiatry Neurol 1991;45:357–9.
(check this in PDF content)
50
Kwak S.E., Kim J.E., Kim D.S. et al. Differential effects of vigabatrin and zonisamide on the neuropeptide Y system in the hippocampus of seizure prone gerbil. Neuropeptides 2005;39(5):507–13.
(check this in PDF content)
51
Kwan P., Brodie M.J. Early identification of refractory epilepsy. N Engl J Med 2000;342(5):314–9.
(check this in PDF content)
52
Kwan P., Brodie M.J. Epilepsy after the first drug fails: substitution or add-on? Seizure 2000;9(7):464–8.
(check this in PDF content)
53
Kwan P., Brodie M.J. Refractory epilepsy: mechanisms and solutions. Expert Rev Neurother 2006;6(3):397–406.
(check this in PDF content)
54
Lee Y.J., Kang H.C., Seo J.H. et al. Efficacy and tolerability of adjunctive therapy with zonisamide in childhood intractable epilepsy. Brain Dev 2010;32(3):208–12.
(check this in PDF content)
55
Leppik I.E. Practical prescribing and longterm efficacy and safety of zonisamide. Epilepsy Res 2006;68 Suppl 2:S17–24.
(check this in PDF content)
56
Leppik I.E. Zonisamide: chemistry, mechanism of action, and pharmacokinetics. Seizure 2004;13 Suppl 1:S5–9; discussion S10.
(check this in PDF content)
57
Lim J., Ko Y.H., Joe S.H. et al. Zonisamide produces weight loss in psychotropic drugtreated psychiatric outpatients. Prog Neuropsychopharmacol Biol Psychiatry 2011;35(8):1918–21.
(check this in PDF content)
58
Lopez-Trigo J., Ortiz-Sanchez P., BlancoHernandez T. Zonisamide and neuropathic pain. Rev Neurol 2007;45(7):429–32.
(check this in PDF content)
59
Lotze T.E., Wilfong A.A. Zonisamide treatment for symptomatic infantile spasms. Neurology 2004:62(2);296–8.
(check this in PDF content)
60
Lu Y., Xiao Z., Yu W. et al. Efficacy and safety of adjunctive zonisamide in adult patients with refractory partial-onset epilepsy: a randomized, double-blind, placebocontrolled trial. Clin Drug Investig 2011;31(4):221–9.
(check this in PDF content)
61
Marazziti D., Rossi L., Baroni S. et al. Novel treatment options of binge eating disorder. Curr Med Chem 2011;18(33):5159–64.
(check this in PDF content)
62
Mares P. Zonisamide suppresses the tonic phase but not the clonic phase of generalized seizures in developing rats. Epilepsy Res 2010;92(2–3):244–8. 6262 RGDN_01_2015 Block.indd 62RGDN_01_2015 Block.indd 6206.04.2015 13:44:4206.04.2015 13:44:42
(check this in PDF content)
63
Marinas A., Villanueva V., Giráldez B.G. et al. Efficacy and tolerability of zonisamide in idiopathic generalized epilepsy. Epileptic Disord 2009;11(1):61–6.
(check this in PDF content)
64
Marmarou A., Pellock J.M. Zonisamide: physician and patient experiences. Epilepsy Res 2005;64(1–2):63–9.
(check this in PDF content)
65
Mirza N.S., Alfirevic A., Jorgensen A. et al. Metabolic acidosis with topiramate and zonisamide: an assessment of its severity and predictors. Pharmacogenet Genomics 2011;21(5):297–302.
(check this in PDF content)
66
Miura H. Zonisamide monotherapy with once-daily dosing in children with cryptogenic localization-related epilepsies: clinical effects and pharmacokinetic studies. Seizure 2004; 13 Suppl 1:S17–23; discussion S24–5.
(check this in PDF content)
67
Miwa H. Zonisamide for the treatment of Parkinson's disease. Expert Rev Neurother 2007;7(9):1077–83.
(check this in PDF content)
68
Mohammadianinejad S.E., Abbasi V., Sajedi S.A. et al. Zonisamide versus topiramate in migraine prophylaxis: a double-blind randomized clinical trial. Clin Neuropharmacol 2011;34(4):174–7.
(check this in PDF content)
69
Montouris G., Abou-Khalil B. The first line of therapy in a girl with juvenile myoclonic epilepsy: should it be valproate or a new agent? Epilepsia 2009;50 Suppl 8:16–20.
(check this in PDF content)
70
Murata M. The discovery of an antiparkinsonian drug, zonisamide. Rinsho Shinkeigaku 2010;50(11):780–2.
(check this in PDF content)
71
Newmark M.E., Dubinsky S. Zonisamide monotherapy in multi-group clinic. Seizure 2004;13(4):223–5.
(check this in PDF content)
72
Ohtahara S. Zonisamide in the management of epilepsy – Japanese experience. Epilepsy Res 2006;68 Suppl 2:S25–33.
(check this in PDF content)
73
Ohtahara S., Yamatogi Y. Safety of zonisamide therapy: prospective follow-up survey. Seizure 2004:13 Suppl 1:S50–5; discussion S56.
(check this in PDF content)
74
Oles K.S., Bell W.L. Zonisamide concentrations during pregnancy. Ann Pharmacother 2008;42(7):1139–41.
(check this in PDF content)
75
O'Rourke D., Flynn C., White M. et al. Potential efficacy of zonisamide in refractory juvenile myoclonic epilepsy: retrospective evidence from an Irish compassionate-use case series. Ir Med J 2007;100(4):431–3.
(check this in PDF content)
76
Park S.P., Hwang Y.H., Lee H.W. et al. Long-term cognitive and mood effects of zonisamide monotherapy in epilepsy patients. Epilepsy Behav 2008;12(1):102–8.
(check this in PDF content)
77
Park S.P., Kim S.Y., Hwang Y.H. et al. Long term efficacy and safety of zonisamide monotherapy in epilepsy patients. J Clin Neurol 2007;3(4):175–80.
(check this in PDF content)
78
Ragueneau-Majlessi I., Levy R.H., Bergen D. et al. Carbamazepine pharmacokinetics are not affected by zonisamide: in vitro mechanistic study and in vivo clinical study in epileptic patients. Epilepsy Res 2004;62(1):1–11.
(check this in PDF content)
79
Russo E., Citraro R., Scicchitano F. et al. Effects of early long-term treatment with antiepileptic drugs on development of seizures and depressive-like behavior in a rat genetic absence epilepsy model. Epilepsia 2011;52(7):1341–50.
(check this in PDF content)
80
Sackellares J.C., Ramsay R.E., Wilder B.J. et al. Randomized, controlled clinical trial of zonisamide as adjunctive treatment for refractory partial seizures. Epilepsia 2004;45(6):610–7.
(check this in PDF content)
81
Santos C.C., Brotherton T. Use of zonisamide in pediatric patients. Pediatr Neurol 2005;33(1):12–4.
(check this in PDF content)
82
Schulze-Bonhage A. Zonisamide in the treatment of epilepsy. Expert Opin Pharmacother 2010;11(1):115–26.
(check this in PDF content)
83
Seino M. Review of zonisamide development in Japan. Seizure 2004; 13 Suppl 1:S2–4.
(check this in PDF content)
84
Seki T., Kumagai N., Maezawa M. Effects of zonisamide monotherapy in children with epilepsy. Seizure 2004;13 Suppl 1:S26–32.
(check this in PDF content)
85
Sills G., Brodie M. Pharmacokinetics and drug interactions with zonisamide. Epilepsia 2007;48(3):435–41.
(check this in PDF content)
86
Sobieszek G., Borowicz K.K., KimberTrojnar Z. et al. Zonisamide: a new antiepileptic drug. Pol J Pharmacol 2003;55(5):683–9.
(check this in PDF content)
87
Suzuki Y., Imai K., Toribe Y. et al. Longterm response to zonisamide in patients with West syndrome. Neurology 2002;58(10):1556–9.
(check this in PDF content)
88
Szaflarski J.P. Effects of zonisamide on the electroencephalogram of a patient with juvenile myoclonic epilepsy. Epilepsy Behav 2004;5(6):1024–6.
(check this in PDF content)
89
Takahashi S., Ohinata J., Suzuki N. et al. Molecular analysis and anticonvulsant therapy in two patients with glucose transporter 1 deficiency syndrome: a successful use of zonisamide for controlling the seizures. Epilepsy Res 2008;80(1):18–22.
(check this in PDF content)
90
Tan H.J., Martland T.R., Appleton R.E., Kneen R. Effectiveness and tolerability of zonisamide in children with epilepsy: a retrospective review. Seizure 2010;19(1): 31–5.
(check this in PDF content)
91
Thone J., Leniger T., Splettstosser F., Wiemann M. Antiepileptic activity of zonisamide on hippocampal CA3 neurons does not depend on carbonic anhydrase inhibition. Epilepsy Res 2008;79(2–3):105–11.
(check this in PDF content)
92
Tosches W.A., Tisdell J. Long-term efficacy and safety of monotherapy and adjunctive therapy with zonisamide. Epilepsy Behav 2006;8(3):522–6.
(check this in PDF content)
93
Tsao C.Y. Current trends in the treatment of infantile spasms. Neuropsychiatr Dis Treat 2009;5:289–99.
(check this in PDF content)
94
Ueda Y., Doi T., Tokumaru J., Willmore L.J. Effect of zonisamide on molecular regulation of glutamate and GABA transporter proteins during epileptogenesis in rats with hippocampal seizures. Brain Res Mol Brain Res 2003;116(1–2):1–6.
(check this in PDF content)
95
Uthman B.M., Miller G.S., Montouris G. et al.; Zonisamide 501 Study Group. Safety of 25- and 50-mg capsules in the initiation of zonisamide therapy in patients with epilepsy: an uncontrolled, open-label study. Curr Med Res Opin 2004;20(6):837–42.
(check this in PDF content)
96
Vossler D.G., Conry J.A., Murphy J.V.; ZNS-502/505 PME Study Group. Zonisamide for the treatment of myoclonic seizures in progressive myoclonic epilepsy: an open-label study. Epileptic Disord 2008;10(1):31–4.
(check this in PDF content)
97
Wellmer J., Wellmer S., Bauer J. The impact of zonisamide on weight. A clinical study in 103 patients with epilepsy. Acta Neurol Scand 2009;119(4):233–8.
(check this in PDF content)
98
Wellmer S., Wellmer J., Bauer J. Zonisamide as add-on treatment for focal epilepsies. An outcome analysis of 74 patients. Nervenarzt 2008;79(12):1416, 1418–23.
(check this in PDF content)
99
White J.R., Walczak T.S., Marino S.E. et al. Zonisamide discontinuation due to psychiatric and cognitive adverse events: a case-control study. Neurology 2010;75(6):513–8.
(check this in PDF content)
100
Wilfong A., Schultz R. Zonisamide for absence seizures. Epilepsy Res 2005; 64(1–2):31–4.
(check this in PDF content)
101
Wilfong A.A. Zonisamide monotherapy for epilepsy in children and young adults. Pediatr Neurol 2005;32(2):77–80.
(check this in PDF content)
102
Wilfong A.A., Willmore L.J. Zonisamide – a review of experience and use in partial seizures. Neuropsychiatr Dis Treat 2006;2(3):269–80.
(check this in PDF content)
103
Wroe S. Zonisamide and renal calculi in patients with epilepsy: how big an issue? Curr Med Res Opin 2007;23(8):1765–73.
(check this in PDF content)
104
Wroe S.J., Yeates A.B., Marshall A. Longterm safety and efficacy of zonisamide in patients with refractory partial-onset epilepsy. Acta Neurol Scand 2008;118(2):87–93.
(check this in PDF content)
105
Yagi K., Seki T. Zonisamide in еpilepsy therapy: remarkable improvement in 100 cases. 1st ed. Japan, Tokyo: Sozo Shuppan, 1994.
(check this in PDF content)
106
Yamauchi T., Aikawa H. Efficacy of zonisamide: our experience. Seizure 2004; 13 Suppl 1:S41–8; discussion S49.
(check this in PDF content)
107
Yanagaki S., Oguni H., Yoshii K. et al. Zonisamide for West syndrome: a comparison of clinical responses among different titration rate. Brain Dev 2005;27(4):286–90.
(check this in PDF content)
108
You S.J., Kang H.C., Kim H.D. et al. Clinical efficacy of zonisamide in Lennox– Gastaut syndrome: Korean multicentric experience. Brain Dev 2008;30(4):287–90.
(check this in PDF content)
109
Yum M.S., Ko T.S. Zonisamide in West syndrome: an open label study. Epileptic Disord 2009;11(4):339–44.
(check this in PDF content)
110
Zaccara G., Specchio L.M. Long-term safety and effectiveness of zonisamide in the treatment of epilepsy: a review of the literature. Neuropsychiatr Dis Treat 2009;5:249–59.
(check this in PDF content)
111
Zaccara G., Tramacere L., Cincotta M. Drug safety evaluation of zonisamide for the treatment of epilepsy. Expert Opin Drug Saf 2011;10(4):623–31.
(check this in PDF content)
112
Zareba G. Zonisamide: review of its use in epilepsy therapy. Drugs Today (Barc) 2005;41(9):589–97. 6363 RGDN_01_2015 Block.indd 63RGDN_01_2015 Block.indd 6306.04.2015 13:44:4206.04.2015 13:44:42
(check this in PDF content)